Testing moxonidine and amlodipine in obese adults with high blood pressure
Compares moxonidine, amlodipine and placebo in obese adults with high blood pressure.
Key facts
- Who runs it
- Vanderbilt University Medical Center
- Where
- Nashville, United StatesSee the site
- Trial code
- Registry title
- Sympathetic Mechanisms in Obesity-Crossover Design
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 12 people, planned
- Started
- 20 May 2022
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Amlodipine
- Moxonidine
- Placebo
- Record updated
- 27 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 who are obese and have high blood pressure. It tests two weeks of nerve-signal blockade on sugar production in the body.
- Age
- 18 to 65 years
- Sex
- Men and women
- Disease stage
- High blood pressure (readings above 130/85 mmHg, or already taking blood pressure medicine) and obesity (BMI of 30 kg/m2 or more).
- Earlier treatment
- People on long-term steroid treatment (more than 7 days in a row in 1 month) or who took any investigational drug in the past month cannot join.
Main reasons for not taking part
- Pregnancy or breast feeding
- Current smokers or heavy smoking history (more than 2 packs a day)
- Type I diabetes
- Heart disease other than high blood pressure, or serious stroke-type brain vessel disease
- Impaired kidney function
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Males and females of all races between 18 and 65 years of age
- Hypertension defined by two or more properly measured seated blood pressure readings >130/85 mmHg or currently on antihypertensive medication
- Obesity will be defined as having a body mass index (BMI) ≥ 30 kg/m2
- Able and willing to provide informed consent
Who cannot take part
- Previous allergic reaction to study medications
- Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy
- Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)
- Treatment with any investigational drug in the 1 month preceding the study
- Current smokers or history of heavy smoking (>2 packs/day)
- History of alcohol or drug abuse
- Type I diabetes
- History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack
- History or presence of immunological or hematological disorders
- Other factors which in the investigator's opinion would prevent the subject from completing the protocol (i.e., clinically significant abnormalities on clinical, mental examination or laboratory testing or inability to comply with protocol, inability to find IV access)
- Pregnancy or breast feeding
- Impaired renal function
- Inability to give, or withdraw, informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Vanderbilt University Medical CenterNashville, United StatesContact: Cynthia Laws, MSTaking people
About the trial
What the trial wants to find out
We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm). The order of the studies will be determined using computer-generated randomization. Patients will be blinded as to which treatment they are receiving on each day. An investigator blinded to the treatment assignment will perform the analysis of the data.
The 3 groups in the trial
- PlaceboPlacebo, for comparison
Subjects will received 2 weeks of capsules containing placebo.
- AmlodipineExisting treatment, for comparison
Subjects will received 2 weeks of capsules containing amlodipine.
- MoxonidineTreatment being tested
Subjects will received 2 weeks of capsules containing moxonidine.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity, Crossover Design Study.
- Plain-language title
- Testing moxonidine and amlodipine in obese adults with high blood pressureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05312892, who can take part
- Record updated
- 27 February 2026